2023
Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies
Thomas A, Gitto M, Shah S, Saito Y, Tirziu D, Chieffo A, Stefanini G, Lansky A. Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100607. PMID: 39130709, PMCID: PMC11307978, DOI: 10.1016/j.jscai.2023.100607.Peer-Reviewed Original ResearchDual antiplatelet therapyAntiplatelet regimensPatient-specific risk profileShorter DAPT durationDuration of therapyPercutaneous coronary interventionDAPT strategyIschemic riskAntiplatelet therapyDAPT durationAntiplatelet strategiesCoronary interventionOngoing trialsMajor trialsRecent trialsPractice guidelinesFuture therapiesRisk profileTherapyStent technologyTrialsRegimensNumber of trialsSignificant reductionSignificant changes
2021
Meta-Analysis of Gender Disparities in In-hospital Care and Outcomes in Patients with ST-Segment Elevation Myocardial Infarction
Shah T, Haimi I, Yang Y, Gaston S, Taoutel R, Mehta S, Lee HJ, Zambahari R, Baumbach A, Henry TD, Grines CL, Lansky A, Tirziu D. Meta-Analysis of Gender Disparities in In-hospital Care and Outcomes in Patients with ST-Segment Elevation Myocardial Infarction. The American Journal Of Cardiology 2021, 147: 23-32. PMID: 33640366, DOI: 10.1016/j.amjcard.2021.02.015.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPrimary PCIMyocardial infarctionMajor bleedingBalloon timeST-segment elevation myocardial infarctionMyocardial infarction outcomesRepeat myocardial infarctionFirst medical contactElevation myocardial infarctionPercutaneous coronary interventionSpecific patient characteristicsRate of mortalityAspirin usageMore comorbiditiesAntiplatelet therapyHospital outcomesP2Y12 inhibitorsCoronary interventionLonger doorPatient characteristicsMedical contactClinical outcomesGender disparitiesSuboptimal treatmentDifferential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy
Saito Y, Wijns W, Baumbach A, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Differential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy. Catheterization And Cardiovascular Interventions 2021, 99: 357-365. PMID: 33502809, DOI: 10.1002/ccd.29468.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapyTarget lesion failureDrug-eluting stentsTarget vessel myocardial infarctionBiodegradable polymer drug-eluting stentsChronic coronary syndromeAcute coronary syndromeDAPT discontinuationVessel myocardial infarctionAntiplatelet therapyCoronary syndromeMyocardial infarctionDurable polymer drug-eluting stentsIschemia-driven target lesion revascularizationIschemic coronary artery diseaseTarget lesion revascularizationIschemia-driven revascularizationPercutaneous coronary interventionCoronary artery diseaseIschemic coronary diseaseComer studyLesion revascularizationDAPT durationLesion failurePrimary endpoint
2020
Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Saito Y, Nazif T, Baumbach A, Tchétché D, Latib A, Kaple R, Forrest J, Prendergast B, Lansky A. Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiology 2020, 5: 92-101. PMID: 31721980, DOI: 10.1001/jamacardio.2019.4367.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementAdjunctive antithrombotic therapyDual antiplatelet therapyAntithrombotic therapyAntiplatelet therapyValve replacementAortic stenosisAortic stenosis (AS) undergoing transcatheter aortic valve replacementSevere symptomatic aortic stenosisSurgical aortic valve replacementGuideline-recommended regimenOral anticoagulant useSevere aortic stenosisSingle antiplatelet therapySymptomatic aortic stenosisPatient risk factorsOngoing clinical trialsRisk prediction modelMajor bleedingOral anticoagulationAnticoagulant useStroke riskTAVR proceduresThrombotic risk
2019
Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion
Attaran RR, Ozdemir D, Lin IH, Mena-Hurtado C, Lansky A. Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2019, 7: 527-534. PMID: 31203859, DOI: 10.1016/j.jvsv.2019.01.058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsEndovascular ProceduresFemaleHumansIliac VeinMaleMay-Thurner SyndromeMiddle AgedPlatelet Aggregation InhibitorsPostthrombotic SyndromeProsthesis DesignRecurrenceRetrospective StudiesStentsTime FactorsTreatment OutcomeVascular PatencyVena Cava, InferiorVenous ThrombosisConceptsAcute deep vein thrombosisPost-thrombotic syndromeDeep vein thrombosisMay-Thurner syndromeDuration of anticoagulationAntiplatelet therapyPatency ratesIliocaval stentingIpsilateral deep vein thrombosisIliocaval venous stentingPrimary patency rateStent patency ratesCommon femoral veinVariety of indicationsLarge teaching hospitalVein thrombosisVenous stentingRetrospective reviewDVT groupStent groupFemoral veinProcedural dataStent patencyStent occlusionTeaching hospital
2015
Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents.
Grundeken MJ, Lansky A, Tanguay JF, Gershlick A, Baumbach A, Cuisset T. Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents. EuroIntervention 2015, 11: 364-5. PMID: 26196757, DOI: 10.4244/eijv11i3a71.Peer-Reviewed Original Research
2013
First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus-Eluting Stent Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries)
Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W. First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus-Eluting Stent Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries). JACC Cardiovascular Interventions 2013, 6: 1026-1034. PMID: 24055443, DOI: 10.1016/j.jcin.2013.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAdultAgedAged, 80 and overAngina, StableAngina, UnstableAustraliaBelgiumCardiovascular AgentsChromium AlloysCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary StenosisCoronary VesselsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansMaleMiddle AgedMyocardial InfarctionNeointimaNew ZealandPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPolymersProspective StudiesProsthesis DesignSeverity of Illness IndexSirolimusTime FactorsTomography, Optical CoherenceTreatment OutcomeUltrasonography, InterventionalConceptsStent late lumen lossLate lumen lossSirolimus-eluting stentsOptical coherence tomographyIntravascular ultrasoundMajor adverse cardiac eventsSymptomatic coronary artery diseaseCoherence tomographyComplete strut coverageNeointimal volume obstructionUnderwent repeat angiographyAdverse cardiac eventsDual antiplatelet therapyCoronary artery diseaseUnstable angina pectorisDrug-eluting stentsLong-term riskAntiplatelet therapyVolume obstructionCardiac eventsRepeat angiographyAdverse eventsAngina pectorisArtery diseaseI trial
2012
Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome
Boden WE, Lansky A, Angiolillo DJ. Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. The American Journal Of Cardiology 2012, 111: 439-444. PMID: 23168289, DOI: 10.1016/j.amjcard.2012.10.018.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeDual antiplatelet therapyAntiplatelet therapyCoronary syndromeHigh-risk percutaneous coronary interventionUnmet needPotent platelet inhibitionChronic kidney diseaseComplex coronary anatomyFirst-line therapyHigh-risk patientsLow-risk patientsPercutaneous coronary interventionSubgroup of patientsPrevious revascularizationPharmacologic managementCoronary interventionRisk patientsDiabetes mellitusPlatelet inhibitionSuch patientsCoronary anatomyKidney diseaseTherapeutic optionsTreatment options
2011
Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation 2011, 123: 1745-1756. PMID: 21482968, DOI: 10.1161/circulationaha.110.981688.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsClopidogrelCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleHeparinHirudinsHumansMaleMetalsMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPredictive Value of TestsRecombinant ProteinsRisk FactorsTiclopidineTreatment OutcomeTubulin ModulatorsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionElevation myocardial infarctionPercutaneous coronary interventionBare metal stentsDrug-eluting stentsStent thrombosisCoronary interventionMyocardial infarctionMetal stentsBivalirudin monotherapyOnly bare-metal stentsAcute Myocardial Infarction trialIIb/IIIa inhibitorsClopidogrel loading dosePotent antiplatelet therapyProbable stent thrombosisAcute stent thrombosisMyocardial Infarction trialAcute myocardial infarctionAntithrombin therapyHarmonizing OutcomesAntiplatelet therapyIndependent predictorsLow Stent Thrombosis Risk with the XIENCE V® Everolimus‐Eluting Coronary Stent: Evidence from Randomized and Single‐Arm Clinical Trials
BEZENEK S, HERMILLER J, LANSKY A, YAQUB M, HATTORI K, CAO S, SOOD P, SUDHIR K. Low Stent Thrombosis Risk with the XIENCE V® Everolimus‐Eluting Coronary Stent: Evidence from Randomized and Single‐Arm Clinical Trials. Journal Of Interventional Cardiology 2011, 24: 326-341. PMID: 21443551, DOI: 10.1111/j.1540-8183.2011.00628.x.Peer-Reviewed Original ResearchConceptsEverolimus-Eluting Coronary Stent SystemDual antiplatelet therapyXIENCE VST ratesRisk factorsLow stent thrombosis ratesSingle-arm clinical trialOccurrence of STStent thrombosis riskAcademic Research ConsortiumStent thrombosis ratesPotential risk factorsCoronary stent systemLow ST ratesHigh compliance rateSPIRIT FIRSTAntiplatelet therapyThrombosis rateSPIRIT trialComplex patientsThrombosis riskClinical trialsStent systemThin strut designDrug usage5-Year Follow-Up of Polytetrafluoroethylene-Covered Stents Compared With Bare-Metal Stents in Aortocoronary Saphenous Vein Grafts The Randomized BARRICADE (Barrier Approach to Restenosis: Restrict Intima to Curtail Adverse Events) Trial
Stone GW, Goldberg S, O'Shaughnessy C, Midei M, Siegel RM, Cristea E, Dangas G, Lansky AJ, Mehran R. 5-Year Follow-Up of Polytetrafluoroethylene-Covered Stents Compared With Bare-Metal Stents in Aortocoronary Saphenous Vein Grafts The Randomized BARRICADE (Barrier Approach to Restenosis: Restrict Intima to Curtail Adverse Events) Trial. JACC Cardiovascular Interventions 2011, 4: 300-309. PMID: 21435608, DOI: 10.1016/j.jcin.2010.11.013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryChi-Square DistributionCoated Materials, BiocompatibleCoronary AngiographyCoronary Artery BypassCoronary RestenosisFemaleGraft Occlusion, VascularHumansKaplan-Meier EstimateMaleMetalsMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPolytetrafluoroethyleneProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSaphenous VeinStentsThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsSaphenous vein graftsBare metal stentsPercutaneous coronary interventionDiseased saphenous vein graftsHigh-pressure implantationDual antiplatelet therapyTarget vessel failureAntiplatelet therapyMajor secondary end pointEnd pointPrimary end pointSecondary end pointsLong-term prognosisBinary restenosisBMS patientsCoronary interventionVein graftsVessel failureInferior outcomesSaphenous veinDiscrete lesionsPatientsPrior trialsJostentLesions
2010
COMPLIANCE WITH DUAL ANTIPLATELET THERAPY AND SUBSEQUENT ADVERSE EVENTS IN PATIENTS WITH STEMI UNDERGOING STENT IMPLANTATION: ANALYSIS FROM THE HORIZONS-AMI TRIAL
Mehran R, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Caixeta A, Haratani N, Dangas G, Lansky A, Stone G. COMPLIANCE WITH DUAL ANTIPLATELET THERAPY AND SUBSEQUENT ADVERSE EVENTS IN PATIENTS WITH STEMI UNDERGOING STENT IMPLANTATION: ANALYSIS FROM THE HORIZONS-AMI TRIAL. Journal Of The American College Of Cardiology 2010, 55: a185.e1728. DOI: 10.1016/s0735-1097(10)61729-9.Peer-Reviewed Original Research
2007
Six-Month Clinical and Angiographic Results of a Dedicated Drug-Eluting Stent for the Treatment of Coronary Bifurcation Narrowings
Grube E, Buellesfeld L, Neumann FJ, Verheye S, Abizaid A, McClean D, Mueller R, Lansky A, Mehran R, Costa R, Gerckens U, Trauthen B, Fitzgerald PJ. Six-Month Clinical and Angiographic Results of a Dedicated Drug-Eluting Stent for the Treatment of Coronary Bifurcation Narrowings. The American Journal Of Cardiology 2007, 99: 1691-1697. PMID: 17560877, DOI: 10.1016/j.amjcard.2007.01.043.Peer-Reviewed Original ResearchConceptsCoronary bifurcation lesionsBifurcation lesionsDe novo coronary bifurcation lesionsProspective multicenter single-arm studyBiolimus A9-eluting stentMulticenter single-arm studyResult of restenosisTarget lesion revascularizationClinical complication rateSingle-arm studyStent late lossSide branchesDrug-eluting stentsLate stent thrombosisBalloon angioplasty treatmentLesion revascularizationNonbifurcation lesionsAntiplatelet therapyComplication rateAngiographic resultsStent thrombosisBalloon angioplastyPercutaneous interventionAngioplasty treatmentAXXESS stent
2002
Results of the Jostent coronary stent graft implantation in various clinical settings: Procedural and follow‐up results
Gercken U, Lansky AJ, Buellesfeld L, Desai K, Badereldin M, Mueller R, Selbach G, Leon MB, Grube E. Results of the Jostent coronary stent graft implantation in various clinical settings: Procedural and follow‐up results. Catheterization And Cardiovascular Interventions 2002, 56: 353-360. PMID: 12112888, DOI: 10.1002/ccd.10223.Peer-Reviewed Original ResearchConceptsCoronary stent graftSaphenous vein graftsOverall restenosis rateStent graftRestenosis rateCoronary perforationStent restenosisAntiplatelet therapyVein graftsStent implantationComplex lesionsStent edgeStainless steel stentsHigh primary success ratePrimary angiographic success rateAngiographic success ratePrimary success ratePTFE layerIntravascular ultrasound guidanceLate lumen lossStent-graft implantationVein graft lesionsQ-wave MIComplex lesion subsetsTransient ventricular fibrillationProlonged antiplatelet therapy and reduced stenting eliminates late thrombosis after radiation: the SCRIPPS III trial
Teirstein P, Moses J, Leon M, Casterella P, Reilly J, Glap H, Jani S, Balter S, Tripuraneni P, Lansky A, Negoita M, Mehran R. Prolonged antiplatelet therapy and reduced stenting eliminates late thrombosis after radiation: the SCRIPPS III trial. Journal Of The American College Of Cardiology 2002, 39: 65. DOI: 10.1016/s0735-1097(02)80281-9.Peer-Reviewed Original Research
2001
Stent Thrombosis in the Modern Era
Cutlip D, Baim D, Ho K, Popma J, Lansky A, Cohen D, Carrozza J, Chauhan M, Rodriguez O, Kuntz R. Stent Thrombosis in the Modern Era. Circulation 2001, 103: 1967-1971. PMID: 11306525, DOI: 10.1161/01.cir.103.15.1967.Peer-Reviewed Original ResearchMeSH KeywordsAspirinBlood Vessel Prosthesis ImplantationCausalityCoronary DiseaseCoronary ThrombosisEndpoint DeterminationFemaleGraft Occlusion, VascularHumansIncidenceLogistic ModelsMaleMiddle AgedMulticenter Studies as TopicMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicSurvival RateTiclopidineTreatment OutcomeConceptsTotal stent lengthStent thrombosisAntiplatelet therapyStent lengthClinical consequencesFinal minimal lumen diameterLumen diameterNative coronary artery lesionsAngiographic stent thrombosisClinical stent thrombosisHigh-pressure deploymentRoutine antiplatelet therapyCoronary artery lesionsIncidence of deathMinimal lumen diameterProcedure-related variablesSecond-generation stentsCoronary stent trialsSerious clinical consequencesFinal lumen diameterNonrandomized registryAntithrombotic regimensArtery lesionsPersistent dissectionMyocardial infarctionLocalized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting
Leon M, Teirstein P, Moses J, Tripuraneni P, Lansky A, Jani S, Wong S, Fish D, Ellis S, Holmes D, Kerieakes D, Kuntz R. Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting. New England Journal Of Medicine 2001, 344: 250-256. PMID: 11172151, DOI: 10.1056/nejm200101253440402.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryBrachytherapyCombined Modality TherapyCoronary DiseaseCoronary ThrombosisDose-Response Relationship, RadiationDouble-Blind MethodFemaleGamma RaysHumansIridium RadioisotopesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPlatelet Aggregation InhibitorsRadiotherapy DosageSecondary PreventionStentsConceptsIridium-192 groupMyocardial infarctionLate thrombosisStent restenosisIridium-192Intracoronary irradiationTarget lesionsIntracoronary gamma radiation therapyMajor adverse cardiac eventsFrequency of restenosisOral antiplatelet therapyAdverse cardiac eventsComposite of deathPrimary end pointLate myocardial infarctionIntracoronary radiation therapyIncidence of deathRecurrence of restenosisGamma radiation therapyEligible patientsAngiographic restenosisAntiplatelet therapyPlacebo groupCardiac eventsCoronary angioplasty
2000
Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis
Waksman R, Bhargava B, Mintz G, Mehran R, Lansky A, Satler L, Pichard A, Kent K, Leon M. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. Journal Of The American College Of Cardiology 2000, 36: 65-68. PMID: 10898414, DOI: 10.1016/s0735-1097(00)00681-1.Peer-Reviewed Original ResearchConceptsLate total occlusionPlacebo patientsStent restenosisIntracoronary radiationIrradiated groupAntiplatelet therapyTotal occlusionAcute myocardial infarctionEntire study groupUnstable anginaIntracoronary brachytherapyMyocardial infarctionRadiation protocolStudy groupLate thrombosisPatientsRestenosisMultivariate analysisMaximum doseMean timeNew stentTime of radiationVessel wallMonthsOverall rate